BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
11/03/2021
Initial Lawsuit
11/03/2021
Lawsuit Progression
02/03/2022
Investigation regarding statements made by ON24 in connection with its initial public offering (IPO) about customer profiles and contract renewal.
08/10/2021
ON24 announces its financial results for the second quarter of 2021, reducing its full year guidance for total revenue and announcing an expected loss of $(4.3) to $(1.3) million.
“The second quarter of 2021 was a transition quarter where we went from a ‘peak of Covid’ in Q2 2020 to a ’peak of vaccinations’ in Q2 2021 and we exited this quarter with a significantly improved quality of our customer base.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$22.31 | $32.31 | $-10 | -30.95% |
Plaintiff brings this securities class action on behalf of a class consisting of all persons and entities that purchased, or otherwise acquired, ON24 common stock issued in connection with the company’s initial public offering (IPO).
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the surge in COVID-19 customers ON24 observed in the lead up to the IPO consisted of a significant number that did not fit ON24’s traditional customer profile and, as a result, were significantly less likely to renew their contracts.
02/03/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.